{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:46:53Z","timestamp":1792036013753,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Seizures pose a significant burden in patients with primary and secondary brain tumors during the end-of-life period. A wide range of 6 to 56% of clinically observed epileptic seizures at the end of life has been reported. We aimed to analyse the incidence of epileptic seizures at the end of life in brain tumor patients more accurately using not only clinical but also electrophysiological findings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective, single center study included brain tumor patients who died during the stay on the ward or within 7 days after discharge between 01\/2015 and 08\/2020. Clinical observation of seizures derived from the original medical records and EEG findings (within 45 days prior to death) were analyzed to determine the incidence of seizures in that period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 68 eligible patients, 50 patients (73.5%) suffered from seizures within 45 days prior to death, of which n\u2009=\u200924 had a status epilepticus. The diagnosis of seizures\/ status epilepticus was determined either by the presentation of clinical signs in 45 patients and if not, by the detection of a (possible) non-convulsive status epilepticus in the EEG of five patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the presence of neurologically trained staff and with the frequent use of routine EEG, we were able to identify seizures and to distinguish status epilepticus from encephalopathy\/ hypoactive delirium. We detected a higher incidence of seizures and status epilepticus at the end of life in neurooncological patients than previously reported.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-022-04133-1","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T17:11:04Z","timestamp":1667495464000},"page":"277-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors"],"prefix":"10.1007","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9279","authenticated-orcid":false,"given":"Sophie von","family":"Brauchitsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-7471","authenticated-orcid":false,"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7506-0169","authenticated-orcid":false,"given":"Elisabeth","family":"Neuhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dubinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim P.","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8469-5820","authenticated-orcid":false,"given":"Martin","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"4133_CR1","doi-asserted-by":"publisher","unstructured":"Arik Y, Leijten FS, Seute T, Robe PA, Snijders TJ (2014 Jul) Prognosis and therapy of tumor-related versus non-tumor-related status epilepticus: a systematic review and meta-analysis. BMC Neurol 19:14:152. https:\/\/doi.org\/10.1186\/1471-2377-14-152. PMID: 25037845; PMCID: PMC4108966","DOI":"10.1186\/1471-2377-14-152."},{"key":"4133_CR2","doi-asserted-by":"publisher","unstructured":"Weller M, Stupp R, Wick W (2012) Sep;13(9):e375-82 Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(12)70266-8. PMID: 22935237","DOI":"10.1016\/S1470-2045(12)70266-8"},{"key":"4133_CR3","doi-asserted-by":"publisher","unstructured":"Marcuse LV, Lancman G, Demopoulos A, Fields M (2014 Aug) Nonconvulsive status epilepticus in patients with brain tumors. Seizure 23(7):542\u2013547. https:\/\/doi.org\/10.1016\/j.seizure.2014.04.003. Epub 2014 Apr 13. PMID: 24810208","DOI":"10.1016\/j.seizure.2014.04.003."},{"key":"4133_CR4","doi-asserted-by":"publisher","unstructured":"Koekkoek JAF, Dirven L, Reijneveld JC, Postma TJ, Grant R, Pace A, Oberndorfer S, Heimans JJ, Taphoorn MJB (2014 Sep) Epilepsy in the end of life phase of brain tumor patients: a systematic review. Neurooncol Pract 1(3):134\u2013140. https:\/\/doi.org\/10.1093\/nop\/npu018. PMID: 31386028; PMCID: PMC6657388","DOI":"10.1093\/nop\/npu018."},{"key":"4133_CR5","doi-asserted-by":"publisher","unstructured":"Bausewein C, Hau P, Borasio GD, Voltz R (2003) Sep;17(6):558-9 How do patients with primary brain tumours die? Palliat Med. https:\/\/doi.org\/10.1177\/026921630301700615. PMID: 14526892","DOI":"10.1177\/026921630301700615"},{"key":"4133_CR6","doi-asserted-by":"publisher","unstructured":"Faithfull S, Cook K, Lucas C (2005) Oct;19(7):545 \u2013 50 Palliative care of patients with a primary malignant brain tumour: case review of service use and support provided. Palliat Med. https:\/\/doi.org\/10.1191\/0269216305pm1068oa. PMID: 16295287","DOI":"10.1191\/0269216305pm1068oa"},{"key":"4133_CR7","doi-asserted-by":"publisher","unstructured":"Yamanaka R, Koga H, Yamamoto Y, Yamada S, Sano T, Fukushige T (2011 Apr) Characteristics of patients with brain metastases from lung cancer in a palliative care center. Support Care Cancer 19(4):467\u2013473. https:\/\/doi.org\/10.1007\/s00520-010-0838-5. Epub 2010 Mar 10. PMID: 20217148","DOI":"10.1007\/s00520-010-0838-5."},{"key":"4133_CR8","doi-asserted-by":"crossref","unstructured":"Pace A, Di Lorenzo C, Guariglia L, Jandolo B, Carapella CM, Pompili A (2009) Jan;91(1):39\u201343 End of life issues in brain tumor patients. J Neurooncol. doi: 10.1007\/s11060-008-9670-x. Epub 2008 Aug 14. Erratum in: J Neurooncol. 2009 Jan;91(1):45. Lorenzo, Cherubino Di [corrected to Di Lorenzo, Cherubino]. PMID: 18704267","DOI":"10.1007\/s11060-008-9670-x"},{"key":"4133_CR9","doi-asserted-by":"publisher","unstructured":"Pace A, Villani V, Di Lorenzo C, Guariglia L, Maschio M, Pompili A, Carapella CM (2013 Jan) Epilepsy in the end-of-life phase in patients with high-grade gliomas. J Neurooncol 111(1):83\u201386. https:\/\/doi.org\/10.1007\/s11060-012-0993-2. Epub 2012 Oct 20. PMID: 23086435","DOI":"10.1007\/s11060-012-0993-2."},{"key":"4133_CR10","doi-asserted-by":"publisher","unstructured":"Sizoo EM, Braam L, Postma TJ, Pasman HR, Heimans JJ, Klein M, Reijneveld JC, Taphoorn MJ (2010 Nov) Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro Oncol 12(11):1162\u20131166. https:\/\/doi.org\/10.1093\/neuonc\/nop045. Epub 2010 Jan 27. PMID: 20511193; PMCID: PMC3098016","DOI":"10.1093\/neuonc\/nop045."},{"key":"4133_CR11","doi-asserted-by":"publisher","unstructured":"Heese O, Vogeler E, Martens T, Schnell O, Tonn JC, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkhah G, Sabel M, Steiger HJ, Schlegel U, L\u00f6ffler M, Weller M, Westphal M (2013 Sep) German Glioma Network. End-of-life caregivers\u2019 perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. Neuro Oncol 15(9):1251\u20131256. https:\/\/doi.org\/10.1093\/neuonc\/not089Epub 2013 Jun 28. PMID: 23814266; PMCID: PMC3748923","DOI":"10.1093\/neuonc\/not089"},{"issue":"2","key":"4133_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1634\/theoncologist.2012-0247.","volume":"18","author":"EM Sizoo","year":"2013","unstructured":"Sizoo EM, Taphoorn MJ, Uitdehaag B, Heimans JJ, Deliens L, Reijneveld JC, Pasman HR (2013) The end-of-life phase of high-grade glioma patients: dying with dignity? Oncologist 18(2):198\u2013203. https:\/\/doi.org\/10.1634\/theoncologist.2012-0247. Epub 2013 Jan 18. PMID: 23335620; PMCID: PMC3579604","journal-title":"Oncologist"},{"key":"4133_CR13","doi-asserted-by":"publisher","unstructured":"Oberndorfer S, Lindeck-Pozza E, Lahrmann H, Struhal W, Hitzenberger P, Grisold W (2008) Jan-Feb;11(1):26\u201330 The end-of-life hospital setting in patients with glioblastoma. J Palliat Med. https:\/\/doi.org\/10.1089\/jpm.2007.0137. PMID: 18370888","DOI":"10.1089\/jpm.2007.0137"},{"key":"4133_CR14","doi-asserted-by":"publisher","unstructured":"Walbert T, Khan M (2014 Apr) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review. J Neurooncol 117(2):217\u2013224. https:\/\/doi.org\/10.1007\/s11060-014-1393-6. Epub 2014 Feb 13. PMID: 24522718","DOI":"10.1007\/s11060-014-1393-6."},{"key":"4133_CR15","doi-asserted-by":"publisher","unstructured":"Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH (2015 Oct) A definition and classification of status epilepticus\u2013Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 56:1515\u20131523. https:\/\/doi.org\/10.1111\/epi.13121. Epub 2015 Sep 4. PMID: 26336950 10","DOI":"10.1111\/epi.13121"},{"key":"4133_CR16","doi-asserted-by":"publisher","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10;28(11):1963-72. https:\/\/doi.org\/10.1200\/JCO.2009.26.3541. Epub 2010 Mar 15. PMID: 20231676","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"4133_CR17","doi-asserted-by":"crossref","unstructured":"Chukwueke UN, Wen PY (2019) Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. Mar 1;8(1):CNS28. doi: 10.2217\/cns-2018-0007. Epub 2019 Feb 26. PMID: 30806082; PMCID: PMC6499019","DOI":"10.2217\/cns-2018-0007"},{"key":"4133_CR18","doi-asserted-by":"publisher","unstructured":"Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ (2017 Jul) Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol 20(21):2439\u20132449. https:\/\/doi.org\/10.1200\/JCO.2017.72.7511. Epub 2017 Jun 22. PMID: 28640707; PMCID: PMC5516482","DOI":"10.1200\/JCO.2017.72.7511."},{"key":"4133_CR19","doi-asserted-by":"publisher","unstructured":"Kane N, Acharya J, Benickzy S, Caboclo L, Finnigan S, Kaplan PW, Shibasaki H, Pressler R, van Putten MJAM A revised glossary of terms most commonly used by clinical electroencephalographers and updated proposal for the report format of the EEG findings. Revision 2017. Clin Neurophysiol Pract. 2017 Aug 4;2:170\u2013185. https:\/\/doi.org\/10.1016\/j.cnp.2017.07.002. Erratum in: Clin Neurophysiol Pract. 2019 Jun 15;4:133. PMID: 30214992; PMCID: PMC6123891","DOI":"10.1016\/j.cnp.2017.07.002"},{"key":"4133_CR20","doi-asserted-by":"publisher","unstructured":"Hirsch LJ, Fong MWK, Leitinger M, LaRoche SM, Beniczky S, Abend NS, Lee JW, Wusthoff CJ, Hahn CD, Westover MB, Gerard EE, Herman ST, Haider HA, Osman G, Rodriguez-Ruiz A, Maciel CB, Gilmore EJ, Fernandez A, Rosenthal ES, Claassen J, Husain AM, Yoo JY, So EL, Kaplan PW, Nuwer MR, van Putten M, Sutter R, Drislane FW, Trinka E, Gaspard N, American Clinical Neurophysiology Society\u2019s Standardized Critical Care EEG Terminology :2021 Version. J Clin Neurophysiol. 2021 Jan1;38(1):1\u201329. https:\/\/doi.org\/10.1097\/WNP.0000000000000806. PMID: 33475321; PMCID: PMC8135051.","DOI":"10.1097\/WNP.0000000000000806"},{"key":"4133_CR21","doi-asserted-by":"publisher","unstructured":"Leitinger M, Trinka E, Gardella E, Rohracher A, Kalss G, Qerama E, H\u00f6fler J, Hess A, Zimmermann G, Kuchukhidze G, Dobesberger J, Langthaler PB, Beniczky S Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study.Lancet Neurol. 2016Sep; 15(10):1054\u201362. https:\/\/doi.org\/10.1016\/S1474-4422(16)30137-5. Epub 2016 Aug 8. PMID: 27571157.","DOI":"10.1016\/S1474-4422(16)30137-5"},{"key":"4133_CR22","doi-asserted-by":"publisher","unstructured":"Mastall M, Wolpert F, Gramatzki D, Imbach L, Becker D, Schmick A, Hertler C, Roth P, Weller M, Wirsching HG Survival of brain tumour patients with epilepsy. Brain. 2021 Dec 16;144(11):3322\u20133327. https:\/\/doi.org\/10.1093\/brain\/awab188. PMID: 33974079","DOI":"10.1093\/brain\/awab188"},{"key":"4133_CR23","doi-asserted-by":"publisher","unstructured":"Pace A, Di Lorenzo C, Capon A, Villani V, Benincasa D, Guariglia L, Salvati M, Brogna C, Mantini V, Mastromattei A, Pompili A (2012) Feb;15(2):225-7 Quality of care and rehospitalization rate in the last stage of disease in brain tumor patients assisted at home: a cost effectiveness study. J Palliat Med. https:\/\/doi.org\/10.1089\/jpm.2011.0306. PMID: 22339327","DOI":"10.1089\/jpm.2011.0306"},{"key":"4133_CR24","doi-asserted-by":"publisher","unstructured":"Preusser M, de Ribaupierre S, W\u00f6hrer A, Erridge SC, Hegi M, Weller M, Stupp R (2011) Jul;70(1):9\u201321 Current concepts and management of glioblastoma. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.22425. PMID: 21786296","DOI":"10.1002\/ana.22425"},{"key":"4133_CR25","doi-asserted-by":"publisher","unstructured":"Fechner A, Hubert K, Jahnke K, Knake S, Konczalla J, Menzler K, Ronellenfitsch MW, Rosenow F, Strzelczyk A Treatment of refractory and superrefractory status epilepticus with topiramate: A cohort study of 106 patients and a review of the literature. Epilepsia. 2019 Dec;60(12):2448\u20132458. https:\/\/doi.org\/10.1111\/epi.16382. Epub 2019 Nov 11. PMID: 31713232","DOI":"10.1111\/epi.16382"},{"key":"4133_CR26","doi-asserted-by":"publisher","unstructured":"Willems LM, Bauer S, Jahnke K, Voss M, Rosenow F, Strzelczyk A (2020) Aug;34(8):801\u2013826 Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review. CNS Drugs. https:\/\/doi.org\/10.1007\/s40263-020-00747-z. Erratum in: CNS Drugs. 2021 Aug;35(8):921. PMID: 32705422; PMCID: PMC8316215","DOI":"10.1007\/s40263-020-00747-z"},{"key":"4133_CR27","doi-asserted-by":"publisher","unstructured":"Sizoo EM, Koekkoek JA, Postma TJ, Heimans JJ, Pasman HR, Deliens L, Taphoorn MJ, Reijneveld JC (2014) Mar;4(1):77\u201380 Seizures in patients with high-grade glioma: a serious challenge in the end-of-life phase. BMJ Support Palliat Care. https:\/\/doi.org\/10.1136\/bmjspcare-2013-000456. Epub 2013 Jul 23. PMID: 24644775","DOI":"10.1136\/bmjspcare-2013-000456"},{"key":"4133_CR28","doi-asserted-by":"publisher","unstructured":"Maschio M, Sperati F, Dinapoli L, Vidiri A, Fabi A, Pace A, Pompili A, Carapella CM, Cantelmi T (2014 Jun) Weight of epilepsy in brain tumor patients. J Neurooncol 118(2):385\u2013393. https:\/\/doi.org\/10.1007\/s11060-014-1449-7. Epub 2014 May 1. PMID: 24789254","DOI":"10.1007\/s11060-014-1449-7."}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04133-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:09:52Z","timestamp":1670231392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04133-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4133"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04133-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"29 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Independent of the study: A. Strzelczyk reports personal fees and grants from Angelini Pharma\/Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Marinus Pharma, UCB, UNEEG medical, and Zogenix. F. Rosenow reports personal fees from Angelini Pharma\/Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals\/Jazz Pharma, and UCB Pharma and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft (DFG), the Federal Ministry of Education and Research (BMBF), the LOEWE Programme of the State of Hesse, and the European Union. J.P. Steinbach has received honoraria for lectures or advisory board participation or consulting or travel grants from Seagen, Boehringer, Abbvie, Roche, Novocure, Medac and Med-Update. The remaining authors (S. von Brauchitsch, E. Neuhaus, D. Dubinski, M. Voss) declare the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was obtained from the ethics committee of the University Hospital Frankfurt; Goethe University (SNO_01\u201308). This study was performed in accordance with the declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No individual person\u2019s data is included in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}